FDA D.I.S.C.O.: A new drug approval for IDH1 positive relapsed or refractory Acute Myeloid Leukemia

FDA medical oncologists discuss the July 2018 approval of ivosidenib for the treatment of patients with relapsed or refractory acute myeloid leukemia (AML) with a susceptible IDH1 mutation as detected by an FDA-approved test.

Source: FDA Center for Drug Evaluation and Research - What's New - February 26, 2020 Category: Drugs & Pharmacology Authors: FDA Source Type: news